Antimicrobial Resistance of Escherichia coli for Uncomplicated Cystitis: Korean Antimicrobial Resistance Monitoring System · Yu SH, Jung SI, Lee SJ et al.

1. Introduction

Urinary tract infection (UTI) is among the most common bacterial infections in women, affecting one million people worldwide each year, and is classified as uncomplicated or complicated based on the clinical presentation, the anatomical level, and the severity of infection [1,2]. Uncomplicated cystitis (UC) accounts for the greatest number of UTIs, typically affecting healthy non-pregnant women with no anatomic or functional urinary tract abnormalities [3,4]. Almost half of all women experience at least one episode of UC during their lifetime, mainly accompanied by symptoms such as dysuria, urgency, frequency, and a feeling of incomplete bladder emptying [5,6]. Of note, UC is not only common but also has a high recurrence rate; nearly 30% of women who have a UC will have a recurrence within 6–12 months despite treatment [7]. The aforementioned populations are particularly vulnerable to recurrent UC, which can lead to a socioeconomic burden with a negative impact on factors such as the quality of relationships, self-esteem, and the capacity for work [8].

UC can be caused by a variety of pathogens, such as Gram-negative and Gram-positive bacteria as well as fungi [9]. Uropathogenic Escherichia coli, a heterogeneous group of extraintestinal pathogenic E. coli, is the most common causative bacterial pathogen for UC worldwide, accounting for 75–90% of cases [1,10,11]. Therefore, clinicians have traditionally treated UC with empirical antimicrobials, and indeed, the use of antimicrobials has been the most important approach to the treatment of UC, significantly reducing complications and improving quality of life [12]. However, the long-term and injudicious use of antimicrobial agents has promoted the gradual alteration of the normal microbiota and the development of antimicrobial resistance (AMR) [13]. Consequently, the emergence of antimicrobial-resistant bacteria, such as fluoroquinolone-resistant E. coli and extended-spectrum ß-lactamase (ESBL)-producing E. coli, has proved challenging for clinicians treating UTIs, as these bacteria are no longer responsive to antimicrobial agents and can lead to serious complications, including severe illness, prolonged hospitalization, and death [14]. Moreover, in recent years, the proportion of antimicrobial-resistant bacteria, especially multidrug-resistant bacteria (e.g., carbapenem-resistant Enterobacterales), has been rapidly increasing worldwide, and is now considered one of the greatest threats to global health [11,15,16,17]. In fact, numerous organizations (e.g., the World Health Organization and Centers for Disease Control and Prevention) have declared that AMR is a ‘global public health problem’ [18,19]. Thus, the appropriate use of antimicrobial agents is a cornerstone of treating UTIs, and should be based on regional microbiologic characteristics and antibiotic susceptibility information. The investigation and monitoring of AMR is imperative to obtain the correct information on the distribution, microbiologic characteristics, and antibiotic susceptibility of uropathogens in the community.

To date, there have been several efforts to investigate and monitor AMR in the Republic of Korea [20,21,22]. Recently, the Korean Association of Urogenital Tract Infection and Inflammation (KAUTII) established a monitoring system for AMR surveillance, named the Korean Antimicrobial Resistance Monitoring System (KARMS). The KARMS for UTIs is an internet-based study (https://uti.karms.kr/main-page, accessed from 1 January 2023), and is ongoing with the nationwide cooperation of medical centers in the Republic of Korea. The present study aimed to report AMR focusing on the UC patients with microbiologically proven E. coli, the most common causative bacterium for UC worldwide, in the KARMS database in 2023.